Current and emerging strategies for the management of sarcoidosis.

Current and emerging strategies for the management of sarcoidosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Current and emerging strategies for the management of sarcoidosis. Abstract Text:

Eric S White,Joseph P Lynch,

Sarcoidosis is a systemic inflammatory disorder of unknown etiology. Although any organ may be involved, the lungs are most frequently affected. The clinical course of the disease is highly variable, with up to two-thirds of untreated patients experiencing spontaneous remission within 12-24 months of onset of symptoms. When therapy is required, corticosteroids are considered standard, but studies demonstrating their ability to modify the long-term outcome in this disease are lacking. Often, the myriad of adverse side effects of corticosteroids necessitate the addition of immunosuppressants, cytotoxic agents or biologic therapies to maintain disease remission. Unfortunately, optimal therapeutic regimens have not been described. Patients who do not respond to therapy often experience progressive fibrotic changes and end-organ damage, which ultimately may result in significant morbidity or death. Agents commonly used to treat patients with sarcoidosis and emerging therapeutic options are discussed.

Current and emerging strategies for the management of sarcoidosis. Publishing Authors By Initials

ES White,JP Lynch,

For similar hemic and lymphatic diseases: lymphatic diseases: lymphoproliferative disorders: sarcoidosis research abstracts see: hemic and lymphatic diseases: lymphatic diseases: lymphoproliferative disorders: sarcoidosis research

PUBMED ID PMID:

MEDLINE DATE:

Current and emerging strategies for the management of sarcoidosis. Journal Published:

PUBLICATION TYPE: Review

Journal: Expert opinion on pharmacotherapy

VOLUME: 8

Page Numbers: 1293-311

Journal Abbreviation:

ISSN: 1744-7666

DAY: 3

MONTH: Jun

YEAR: 2007

Current and emerging strategies for the management of sarcoidosis. Information

Number of References: 159

LANGUAGE: eng

NlmUniqueID: 100897346

Current and emerging strategies for the management of sarcoidosis. Keywords Mesh Terms:

KEYWORDS: Sarcoidosis

MESH TERMS: physiopathology

Chemical & Substance for Abstract: Current and emerging strategies for the management of sarcoidosis. Information

Substance Name: Immunosuppressive Agents

Registry Number: 0

Grant and Affiliation Information for Current and emerging strategies for the management of sarcoidosis.

AFFILIATION: University of Michigan Medical Center, Division of Pulmonary and Critical Medicine, Department of Internal Medicine, 6301 MSRB III/0642, 1150 W. Medical Center Drive, Ann Arbor, MI 48109-0642, USA. docew@umich.edu

Country: England

AGENCY: United States NHLBI

GRANT: K08 HL070990

ACRONYM: HL

MEDLINETA: Expert Opin Pharmacother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Current and emerging strategies for the management of sarcoidosis Related Publications

• Amphibian lipid levels at metamorphosis correlate to post-metamorphic terrestrial survival.
• Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus.
• Changes in synaptic morphology accompany actin signaling during LTP.
• Chronic hypersensitivity pneumonitis: CT features comparison with pathologic evidence of fibrosis and survival.
• Clinical selection of candidates for mutational testing for cancer susceptibility.
• Current and emerging strategies for the management of sarcoidosis.
• Dietary fish oil deactivates a growth-promoting signaling pathway in hepatoma 7288CTC in Buffalo rats.
• Diindolylquinoxalines: effective indole-based receptors for phosphate anion.
• ENG mutations in MADH4/BMPR1A mutation negative patients with juvenile polyposis.
• Evidence that long-term potentiation occurs within individual hippocampal synapses during learning.
• Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease.
• Follicular development during early pregnancy and the estrous cycle of the sow.
• Fyn-mediated phosphorylation of NR2B Tyr-1336 controls calpain-mediated NR2B cleavage in neurons and heterologous systems.
• GAD antibody positive paraneoplastic stiff person syndrome in a patient with renal cell carcinoma.
• Global analysis of alternative splicing during T-cell activation.
• Grade III Gliomas with Imaging Appearances of Glioblastoma should be Managed as Glioblastoma.
• Hereditary cancer syndrome diagnosis: molecular genetic clues and cancer control.
• Large global effective population sizes in Paramecium.
• Nutrient signaling components controlling protein synthesis in striated muscle.
• Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma.
• Pharmacological therapy for Wegener's granulomatosis.
• Presence or absence of lipopolysaccharide O antigens affects type III secretion by Pseudomonas aeruginosa.
• Rapamycin blunts nutrient stimulation of eIF4G, but not PKCepsilon phosphorylation, in skeletal muscle.
• Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
• Results from an autonomous underwater vehicle towed hydrophone array experiment in Nantucket Sound.
• Tantalus, a 240MeV Dedicated Source of Synchrotron Radiation, 1968-1986.
• The effect of maternal socio-economic status throughout the lifespan on infant birthweight.
• The relative roles of three DNA repair pathways in preventing Caenorhabditis elegans mutation accumulation.
• Toward a consensus in molecular diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome).
• Who should be sent for genetic testing in hereditary colorectal cancer syndromes?